PRKCB and uveitis: After intersection, the top six compounds, with the highest negative scores, were identified as potential therapeutic agents: PKCbeta-inhibitor (BRD-K89687904), kenpaullone, enzastaurin, SB-216763, amylocaine, and BRD-K06817181 were potential therapeutic agents for the treatment of insomnia-associated uveitis (Figures 5A, B).